Twenty-one brokerages covering Bristol Myers Squibb have issued ratings over the past year, with one recommending sell, thirteen recommending hold and seven recommending buy, resulting in a consensus hold verdict. Analysts’ average 12-month price target stands at $56.86, reflecting modest upside potential based on current consensus estimates. Recent revisions include Morgan Stanley moving its underweight target up by one dollar to $37.00 and HSBC reaffirming its hold rating with a $53.00 objective.

Institutional investors and hedge funds, which collectively own approximately 76.4% of shares, have been active in the past two quarters. Harbor Capital Advisors more than doubled its position in the third quarter to 605 shares, while REAP Financial Group increased its stake by 202.8% in the second quarter to 639 shares. Smaller new stakes were established by Trifecta Capital Advisors and Darwin Wealth Management, each investing about $25,000, and Kerr Financial Planning added roughly $35,000 in exposure during the third quarter.

In the third quarter, the company reported earnings of $1.63 per share, beating the consensus estimate of $1.52 by $0.11, on revenues of $12.22 billion versus expectations of $11.75 billion. Revenue grew 2.8% year-over-year, while net margin reached 12.6% and return on equity soared to 76.5%. Management set full-year EPS guidance at a range of 6.40 to 6.60, against analysts’ average projection of 6.74, indicating confidence in continued cash flow generation.

The board approved a quarterly dividend increase to $0.63 per share, up from $0.62, payable February 2 to shareholders of record January 2. This raises the annualized payout to $2.52 and boosts the yield to approximately 4.6%. The dividend payout ratio now stands at 85.1%, reflecting a commitment to returning capital even as the company maintains investment in its late-stage oncology and immunology pipeline.